第15巻 2019年10月　第4号

■綜説

胃癌化学療法の変遷
金沢　義一, 柿沼　大輔, 松野　邦彦, 藤田　逸郎, 萩原　信敏, 松谷　毅, 野村　務, 吉行　俊郎, 加藤　俊二, 吉田　寛
日本医科大学消化器外科

Historical Changes in Chemotherapy for Gastric Cancer in Japan
Yoshikazu Kanazawa, Daisuke Kakinuma, Kunihiko Matsuno, Itsuo Fujita, Nobutoshi Hagiwara, Takeshi Matsutani, Tsutomu Nomura, Toshiro Yoshiyuki, Shunji Kato and Hiroshi Yoshida
Department of Gastrointestinal and Hepato-biliary-pancreatic Surgery, Nippon Medical School

In Japan, the three major treatment options for gastric cancer are gastrectomy, endoscopic mucosal resection, and anticancer drugs (or combinations of the three). The surgical procedures are well established and the results are satisfactory, but there is no prospect of extending surgical approaches beyond the techniques that already exist. On the other hand, remarkable developments have been made in chemotherapy and molecularly-targeted therapy, and these have contributed to a reduction in deaths from gastric cancer. However, patients with gastric cancer that progresses to a certain level are classified as having systemic disease with an increased risk of postoperative recurrence. Therefore, adjuvant chemotherapy aimed at preventing recurrence, such as metastases or peritoneal dissemination, after surgery can be said to be an indispensable partner of surgical treatment. S-1 is still a key drug in gastric cancer treatment, and maintenance of nutrition and skeletal muscle mass after gastrectomy are important for the continuous use of S-1 after surgery. Taking skeletal muscle mass measurements after surgery is a useful and simple was to predict prognosis.

日医大医会誌 2019; 15(4), 155-163

Key words
gastric cancer, chemotherapy, surgery, long-term survival, skeletal muscle mass evaluation

Correspondence to
Yoshikazu Kanazawa, Department of Gastrointestinal and Hepato-biliary-pancreatic Surgery, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-8603, Japan
E-mail：kanazawa-y@nms.ac.jp

受付：2019年7月21日　受理：2019年9月2日